BioVie has completed its previously announced registered direct offering, raising gross proceeds of $6.66 million through the sale of 4,443,000 common shares at $1.50 per share. The company also conducted a concurrent private placement of warrants to purchase up to 4,443,000 shares at an exercise price of $1.37 per share. The total offering expenses were approximately $902,560.The warrants will become exercisable six months after issuance and will expire five years following the initial exercise date. The company plans to use the net proceeds primarily for working capital and general corporate purposes. ThinkEquity served as the sole placement agent for the offering.Following the offering, BioVie adjusted the exercise price of the existing Acuitas warrant from $1.53 to $1.37 per share, in accordance with the warrant's anti-dilution provisions. The Acuitas warrant, which expires on July 15, 2028, was previously issued under a Securities Purchase Agreement dated July 15, 2022.

BioVie has completed its previously announced registered direct offering, raising gross proceeds of $6.66 million through the sale of 4,443,000 common shares at $1.50 per share. The company also conducted a concurrent private placement of warrants to purchase up to 4,443,000 shares at an exercise price of $1.37 per share. The total offering expenses were approximately $902,560.The warrants will become exercisable six months after issuance and will expire five years following the initial exercise date. The company plans to use the net proceeds primarily for working capital and general corporate purposes. ThinkEquity served as the sole placement agent for the offering.Following the offering, BioVie adjusted the exercise price of the existing Acuitas warrant from $1.53 to $1.37 per share, in accordance with the warrant's anti-dilution provisions. The Acuitas warrant, which expires on July 15, 2028, was previously issued under a Securities Purchase Agreement dated July 15, 2022.